The latest news, announcements and press releases from Synfini.
June 17, 2025 – Menlo Park, CA & Cambridge, MA – Synfini Inc., a leader in AI-driven drug discovery, and O2nix Bio, a pioneering biotech company advancing prooxidant therapies, today announced a strategic collaboration to co-discover and develop novel drug candidates targeting FTSJ1, a tRNA-modifying enzyme implicated in metastatic cancer cell survival. This is O2nix Bio’s first collaboration as an independent, privately funded commercial entity, building on its extensive research into biochemical mechanisms that regulate metastasis.
The collaboration will combine O2nix Bio’s proprietary biology platform and scientific leadership in tRNA methylation with Synfini’s AI Cloud Foundry, an end-to-end automated system that accelerates the design-make-test-analyze (DMTA) drug discovery cycle.
“We are thrilled to collaborate with the Synfini team,” said Elena Piskounova, Ph.D., founder and CEO of O2nix Bio. “Their chemistry automation platform, paired with our mechanistic insights into RNA modifications, will allow us to advance first-in-class therapies targeting cancer metastasis—which is responsible for over 90% of cancer-related deaths and still largely untreatable by current therapies.”
This is the News section of the company profile page for Synfini on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
